Miller, Jonjo;
Campain, Nicholas;
Boydell, Anna-Rita;
Warren, Hannah;
Vito, Ivy;
Neves, Joana;
Mumtaz, Faiz;
... Tran, Maxine GB; + view all
(2022)
‘Case of the Month’ from the Specialist Centre for Kidney Cancer, Royal Free London Hospital, UK: 99mTc-sestamibi SPECT-CT to differentiate renal cell carcinoma from benign oncocytoma.
BJU International
, 129
(1)
pp. 28-31.
10.1111/bju.15652.
Preview |
Text
Warren_mibi revisions2_clean.pdf Download (379kB) | Preview |
Abstract
Our first patient (P1) is a 69-year-old male with a 4-year history of a progressively enlarging left renal upper pole mass; contrast-enhanced CT demonstrated a 3.4-cm lesion in 2017, increasing in size on sequential cross-sectional imaging to 6.0 cm as of March 2021. A renal tumour biopsy (RTB) was performed in 2020 when the tumour measured 5.6 cm and demonstrated cells in a solid nest and trabeculae pattern, with eosinophilic cytoplasm, hyperchromatic nuclei, and inconspicuous nucleoli. Immunohistochemistry was CD117, e-cadherin (incomplete) and CD10 positive, cytokeratin 7 and vimentin negative, consistent with a diagnosis of oncocytoma [1]. The {99}^mtechnetium ({99m}^Tc)-sestamibi single-photon emission CT (SPECT)-CT showed increased uptake within the tumour, consistent with the histological diagnosis of oncocytoma (Fig. 1). As the mass continues to enlarge, and the patient remains keen for non-surgical active treatment, cryotherapy is being considered as an alternative treatment option.
Archive Staff Only
 |
View Item |
